{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:55:21Z","timestamp":1787162121034,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC2508900"],"award-info":[{"award-number":["2023YFC2508900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Innovation Fund for Medical Sciences, CIFMS","award":["2023-I2M-2-007"],"award-info":[{"award-number":["2023-I2M-2-007"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070192"],"award-info":[{"award-number":["82070192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["22HHXBSS00034"],"award-info":[{"award-number":["22HHXBSS00034"]}]},{"DOI":"10.13039\/501100006606","name":"Tianjin Natural Science Foundation","doi-asserted-by":"crossref","award":["23JCZXJC00220"],"award-info":[{"award-number":["23JCZXJC00220"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02526-y","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T01:35:25Z","timestamp":1747013725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory\/relapsed acute myeloid leukemia"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04645199","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ni","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2526_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/cancers11020224","volume":"11","author":"F Ferrara","year":"2019","unstructured":"Ferrara F, Lessi F, Vitagliano O, Birkenghi E, Rossi G. Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers (Basel). 2019;11:224.","journal-title":"Cancers (Basel)"},{"key":"2526_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.beha.2018.09.006","volume":"31","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC. Is there a standard of care for relapsed AML? Best Pract Res Clin Haematol. 2018;31:384\u20136.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2526_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.1995.13.1.11","volume":"13","author":"E Archimbaud","year":"1995","unstructured":"Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol. 1995;13:11\u20138.","journal-title":"J Clin Oncol"},{"key":"2526_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s002770050425","volume":"77","author":"W Kern","year":"1998","unstructured":"Kern W, Aul C, Maschmeyer G, Kuse R, Kerkhoff A, Grote-Metke A, et al. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group. Ann Hematol. 1998;77:115\u201322.","journal-title":"Ann Hematol"},{"key":"2526_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/bjh.16355","volume":"188","author":"J Loke","year":"2020","unstructured":"Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188:129\u201346.","journal-title":"Br J Haematol"},{"key":"2526_CR6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","volume":"5","author":"EAM Feijen","year":"2019","unstructured":"Feijen EAM, Leisenring WM, Stratton KL, Ness KK, van der Pal HJH, van Dalen EC, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019;5:864\u201371.","journal-title":"JAMA Oncol"},{"key":"2526_CR7","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1182\/blood-2023-187351","volume":"142","author":"IE Pinar","year":"2023","unstructured":"Pinar IE, Celik S, Polat MG, Karatas AF, Dogan A, Iltar U, et al. Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: patient registration study of Turkish Society of Hematology-Acute Myeloid Leukemia Working Group. Blood. 2023;142:5838.","journal-title":"Blood"},{"key":"2526_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419\u201336.","journal-title":"Clin Pharmacokinet"},{"key":"2526_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.ejpb.2008.05.019","volume":"70","author":"C Li","year":"2008","unstructured":"Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, et al. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm. 2008;70:657\u201365.","journal-title":"Eur J Pharm Biopharm"},{"key":"2526_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10637-021-01182-7","volume":"40","author":"L Wang","year":"2022","unstructured":"Wang L, Cao J, Li C, Wang X, Zhao Y, Li T, et al. Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial. Invest New Drugs. 2022;40:330\u20139.","journal-title":"Invest New Drugs"},{"key":"2526_CR11","first-page":"365","volume":"32","author":"YQ Jiao","year":"2024","unstructured":"Jiao YQ, Xiong H, Chen Z, Yang L, Tao F, Sun M, et al. Clinical analysis of mitoxantrone liposome in the treatment of children with high-risk acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024;32:365\u20139.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2526_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2526_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/sj.leu.2401066","volume":"12","author":"W Kern","year":"1998","unstructured":"Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, et al. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia. 1998;12:1049\u201355.","journal-title":"Leukemia"},{"key":"2526_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s002770050239","volume":"73","author":"IM Huhmann","year":"1996","unstructured":"Huhmann IM, Watzke HH, Geissler K, Gisslinger H, Jager U, Knobl P, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol. 1996;73:265\u201371.","journal-title":"Ann Hematol"},{"key":"2526_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126:319\u201327.","journal-title":"Blood"},{"key":"2526_CR16","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.3324\/haematol.2018.204792","volume":"104","author":"AB Halpern","year":"2019","unstructured":"Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, et al. Phase I\/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed\/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. Haematologica. 2019;104:e143\u20136.","journal-title":"Haematologica"},{"key":"2526_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","volume":"80","author":"A Wierzbowska","year":"2008","unstructured":"Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Holowiecki J, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80:115\u201326.","journal-title":"Eur J Haematol"},{"key":"2526_CR18","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1200\/JCO.1991.9.7.1210","volume":"9","author":"S Amadori","year":"1991","unstructured":"Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol. 1991;9:1210\u20134.","journal-title":"J Clin Oncol"},{"key":"2526_CR19","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","volume":"23","author":"EJ Feldman","year":"2005","unstructured":"Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O\u2019Connor J, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23:4110\u20136.","journal-title":"J Clin Oncol"},{"key":"2526_CR20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/ajh.21857","volume":"85","author":"HE Kohrt","year":"2010","unstructured":"Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, Majeti R, et al. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Am J Hematol. 2010;85:877\u201381.","journal-title":"Am J Hematol"},{"key":"2526_CR21","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1200\/JCO.2004.07.048","volume":"22","author":"PL Greenberg","year":"2004","unstructured":"Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004;22:1078\u201386.","journal-title":"J Clin Oncol"},{"key":"2526_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3892\/mco.2015.679","volume":"4","author":"S Wei","year":"2016","unstructured":"Wei S, Mi Y, Wei H, Lin D, Liu K, Gong B, et al. Cyclophosphamide combined with mitoxantrone and cytarabine is an effective salvage regimen for patients with acute myeloid leukemia who experienced primary induction failure or relapse. Mol Clin Oncol. 2016;4:285\u20139.","journal-title":"Mol Clin Oncol"},{"key":"2526_CR23","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","volume":"23","author":"DA Breems","year":"2005","unstructured":"Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969\u201378.","journal-title":"J Clin Oncol"},{"key":"2526_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/leu.2011.25","volume":"25","author":"P Chevallier","year":"2011","unstructured":"Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, et al. A new Leukemia Prognostic Scoring System for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia. 2011;25:939\u201344.","journal-title":"Leukemia"},{"key":"2526_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","volume":"29","author":"EJ Feldman","year":"2011","unstructured":"Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29:979\u201385.","journal-title":"J Clin Oncol"},{"key":"2526_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.leukres.2012.07.006","volume":"36","author":"EJ Feldman","year":"2012","unstructured":"Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012;36:1283\u20139.","journal-title":"Leuk Res"},{"key":"2526_CR27","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","volume":"34","author":"WS Lim","year":"2010","unstructured":"Lim WS, Tardi PG, Dos Santos N, Xie X, Fan M, Liboiron BD, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34:1214\u201323.","journal-title":"Leuk Res"},{"key":"2526_CR28","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392.","journal-title":"J Clin Oncol"},{"key":"2526_CR29","first-page":"131","volume":"10","author":"YL Franco","year":"2018","unstructured":"Franco YL, Vaidya TR, Ait-Oudhia S. Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer (Dove Med Press). 2018;10:131\u201341.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2526_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3727\/096504016X14586627440156","volume":"24","author":"A Im","year":"2016","unstructured":"Im A, Amjad A, Agha M, Raptis A, Hou JZ, Farah R, et al. Mitoxantrone and etoposide for the treatment of acute myeloid leukemia patients in first relapse. Oncol Res. 2016;24:73\u201380.","journal-title":"Oncol Res"},{"key":"2526_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107468","volume":"139","author":"S Zhong","year":"2024","unstructured":"Zhong S, Kurish H, Walchack R, Li H, Edwards J, Singh A, et al. Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia. Leuk Res. 2024;139: 107468.","journal-title":"Leuk Res"},{"key":"2526_CR32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/ajh.25838","volume":"95","author":"S Christian","year":"2020","unstructured":"Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, et al. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020;95:937\u201343.","journal-title":"Am J Hematol"},{"key":"2526_CR33","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1182\/blood-2024-203401","volume":"144","author":"L Hui","year":"2024","unstructured":"Hui L, Jiyi F, Zheng B, Lianjie H, Yaqiong L, Xin W, et al. Efficacy and safety of dose-tailored mitoxantrone liposomes combined with cytarabine and venetoclax in newly diagnosed acute myeloid leukemia (non-M3) based on marrow leukemic cellularity. Blood. 2024;144:6068.","journal-title":"Blood"},{"key":"2526_CR34","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1182\/blood-2024-209055","volume":"144","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang W, Xu J, Ma J, Wang H, Wu B, et al. Mitoxantrone hydrochloride liposome combined with cytarabine as induction therapy for patients with newly diagnosed secondary acute myeloid leukemia. Blood. 2024;144:6074.","journal-title":"Blood"},{"key":"2526_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7048","author":"B Bhatnagar","year":"2018","unstructured":"Bhatnagar B, Walker AR, Mims AS, Vasu S, Klisovic RB, Behbehani G, et al. Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia. Am Soc Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.7048.","journal-title":"Am Soc Clin Oncol"},{"key":"2526_CR36","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2012.46.4743","volume":"31","author":"M Schaich","year":"2013","unstructured":"Schaich M, Parmentier S, Kramer M, Illmer T, Stolzel F, Rollig C, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol. 2013;31:2094\u2013102.","journal-title":"J Clin Oncol"},{"key":"2526_CR37","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"A Takami","year":"2014","unstructured":"Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20:1785\u201390.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2526_CR38","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","volume":"4","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4:1245\u201353.","journal-title":"JAMA Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02526-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02526-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02526-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:03:26Z","timestamp":1747058606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02526-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2526"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02526-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Blood Diseases Hospital, Chinese Academy of Medical Sciences (IIT2021011-EC-1) approved the research protocol. This study follows the Declaration of Helsinki. This study was registered with clinicaltrials.gov (Identifier, NCT04645199) in 27\/11\/2020. All patients provided written and oral informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The subjects gave written informed consent for the publication of any associated data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"727"}}